Dr Rohit Thummalapalli speaks to ecancer about early-phase results evaluating ZL-1310, a novel DLL3-targeting antibody-drug conjugate, in patients with advanced neuroendocrine carcinomas who have progressed after platinum-based chemotherapy.

ZL-1310 demonstrated encouraging antitumor activity, with notable response rates observed across a diverse group of neuroendocrine tumour types.

Importantly, responses were seen even in heavily pretreated patients, including those previously exposed to DLL3-targeted therapies.

The treatment was generally well tolerated, with manageable side effects and a low incidence of high-grade adverse events.

Dr Thummalapalli says that most patients remained on therapy at the time of analysis, reflecting both tolerability and potential clinical benefit.

He concludes by saying that these findings highlight ZL-1310 as a promising new therapeutic option in a setting with significant unmet need, supporting ongoing phase II expansion to further define its efficacy and safety profile.